523 related articles for article (PubMed ID: 27930974)
1. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1.
Zhou G; Zhang F; Guo Y; Huang J; Xie Y; Yue S; Chen M; Jiang H; Li M
Biomed Pharmacother; 2017 Jan; 85():113-119. PubMed ID: 27930974
[TBL] [Abstract][Full Text] [Related]
2. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
Zheng R; Jiang H; Li J; Liu X; Xu H
Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
[TBL] [Abstract][Full Text] [Related]
3. Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Zhu X; Jiang H; Li J; Xu J; Fei Z
Med Sci Monit; 2016 Apr; 22():1435-41. PubMed ID: 27125283
[TBL] [Abstract][Full Text] [Related]
4. Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
Narita M; Shimura E; Nagasawa A; Aiuchi T; Suda Y; Hamada Y; Ikegami D; Iwasawa C; Arakawa K; Igarashi K; Kuzumaki N; Yoshioka Y; Ochiya T; Takeshima H; Ushijima T; Narita M
PLoS One; 2017; 12(2):e0172115. PubMed ID: 28225782
[TBL] [Abstract][Full Text] [Related]
5. MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway.
Jiang J; Feng X; Zhou W; Wu Y; Yang Y
Oncotarget; 2016 Nov; 7(45):73188-73199. PubMed ID: 27690301
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.
Zhou JY; Chen X; Zhao J; Bao Z; Chen X; Zhang P; Liu ZF; Zhou JY
Cancer Lett; 2014 Sep; 351(2):265-71. PubMed ID: 24983493
[TBL] [Abstract][Full Text] [Related]
7. miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells.
Nishijima N; Seike M; Soeno C; Chiba M; Miyanaga A; Noro R; Sugano T; Matsumoto M; Kubota K; Gemma A
Int J Oncol; 2016 Mar; 48(3):937-44. PubMed ID: 26783187
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a human non-small cell lung cancer cell line resistant to gefitinib.
Koizumi F; Shimoyama T; Taguchi F; Saijo N; Nishio K
Int J Cancer; 2005 Aug; 116(1):36-44. PubMed ID: 15761868
[TBL] [Abstract][Full Text] [Related]
9. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
[TBL] [Abstract][Full Text] [Related]
10. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.
Wang F; Meng F; Wong SCC; Cho WCS; Yang S; Chan LWC
Ther Adv Respir Dis; 2020; 14():1753466620915156. PubMed ID: 32552611
[TBL] [Abstract][Full Text] [Related]
12. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G
Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411
[TBL] [Abstract][Full Text] [Related]
13. Zinc-finger E-box-binding homeobox 1 (ZEB1) plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinib.
Nurwidya F; Takahashi F; Winardi W; Tajima K; Mitsuishi Y; Murakami A; Kobayashi I; Nara T; Hashimoto M; Kato M; Hidayat M; Suina K; Hayakawa D; Asao T; Ko R; Shukuya T; Yae T; Shimada N; Yoshioka Y; Sasaki S; Takahashi K
Thorac Cancer; 2021 May; 12(10):1536-1548. PubMed ID: 33764690
[TBL] [Abstract][Full Text] [Related]
14. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
[TBL] [Abstract][Full Text] [Related]
15. MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer.
Bai WD; Ye XM; Zhang MY; Zhu HY; Xi WJ; Huang X; Zhao J; Gu B; Zheng GX; Yang AG; Jia LT
Int J Cancer; 2014 Sep; 135(6):1356-68. PubMed ID: 24615544
[TBL] [Abstract][Full Text] [Related]
16. miRNA-125b regulates apoptosis of human non-small cell lung cancer via the PI3K/Akt/GSK3β signaling pathway.
Wang Y; Zhao M; Liu J; Sun Z; Ni J; Liu H
Oncol Rep; 2017 Sep; 38(3):1715-1723. PubMed ID: 28713974
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment with Epimedium koreanum Nakai extract and gefitinib overcomes drug resistance caused by T790M mutation in non-small cell lung cancer cells.
Song J; Zhong R; Huang H; Zhang Z; Ding D; Yan H; Sun E; Jia X
Nutr Cancer; 2014; 66(4):682-9. PubMed ID: 24738693
[TBL] [Abstract][Full Text] [Related]
18. BENC-511, a novel PI3K inhibitor, suppresses metastasis of non-small cell lung cancer cells by modulating β-catenin/ZEB1 regulatory loop.
Zhang Q; Zhou L; Guan Y; Cheng Y; Han X
Chem Biol Interact; 2018 Oct; 294():18-27. PubMed ID: 30125547
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.
Wang YS; Wang YH; Xia HP; Zhou SW; Schmid-Bindert G; Zhou CC
Asian Pac J Cancer Prev; 2012; 13(1):255-60. PubMed ID: 22502680
[TBL] [Abstract][Full Text] [Related]
20. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
